Cingulate Inc.(CING)

Biotechnology · Kansas City, KS

$4.92+0.17 (+3.58%)

Delayed quote: Oct 6, 2026, 10:50 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T14:51:26.755Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:51:26.755Z.

Quote observation: 2026-10-06T14:50:18.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 66,267,657
Total debt · period ending 2026-06-30: 6,290,880
Cash · period ending 2026-06-30: 28,402,819
TTM free cash flow · period ending 2026-06-30: -20,938,580

FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CING EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CING Competitors' EV/FCF Ratio

CING

Cingulate Inc.

Current

Market Cap

$66.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs CING

Market Cap

$64.71M

EV/FCF Ratio

N/A

TTM Avg

1.41x

3Y Avg

1.41x

5Y Avg

1.41x

FBIO

Fortress Biotech, Inc.

vs CING

Market Cap

$67.60M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GOSS

Gossamer Bio, Inc.

vs CING

Market Cap

$64.94M

EV/FCF Ratio

N/A

TTM Avg

54.90x

3Y Avg

54.90x

5Y Avg

54.90x

INCR

InterCure Ltd.

vs CING

Market Cap

$64.68M

EV/FCF Ratio

14.63x

TTM Avg

12.61x

3Y Avg

12.61x

5Y Avg

118.68x

IBIO

iBio, Inc.

vs CING

Market Cap

$68.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRS

Kalaris Therapeutics Inc

vs CING

Market Cap

$63.30M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CSBR

Champions Oncology, Inc.

vs CING

Market Cap

$69.26M

EV/FCF Ratio

N/A

TTM Avg

16.52x

3Y Avg

23.77x

5Y Avg

35.86x

ALPS

Alps Group Inc

vs CING

Market Cap

$63.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs CING

Market Cap

$61.79M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Cingulate Inc. (CING)	$66.27M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$64.71M	N/A	1.41x	1.41x	1.41x
Fortress Biotech, Inc. (FBIO)vs ›	$67.60M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$64.94M	N/A	54.90x	54.90x	54.90x
InterCure Ltd. (INCR)vs ›	$64.68M	14.63x	12.61x	12.61x	118.68x
iBio, Inc. (IBIO)vs ›	$68.49M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$63.30M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.26M	N/A	16.52x	23.77x	35.86x
Alps Group Inc (ALPS)vs ›	$63.23M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$61.79M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

CING EV/FCF Ratio Metrics

CING Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics